Aram Hong

A wristband, a laser, and a refusal to break the skin

Most founders pitch a market. Aram Hong pitched a physics problem - and then signed MIT to help him solve it. His company, Apollon, is built on a single contrarian wager: that the faint, scattered glimmer a laser leaves behind when it bounces off molecules can be read, sorted, and turned into a number, all from a device smaller than a smartwatch.

That glimmer has a name - Raman scattering - and for decades it lived inside laboratory benches the size of refrigerators. The reigning assumption was that it would stay there. Hong's bet was the opposite. As CEO and co-founder of Apollon, he took a 2020 finding published in Science Advances showing glucose could be measured directly with laser light, and asked the only question that mattered to him: could the refrigerator become a wristband?

The answer he is assembling, piece by peer-reviewed piece, is yes. The device is called MOGLU. It does not puncture skin. It does not need a sensor swapped out every two weeks. It sits on the wrist or arm, fires an 830-nanometer laser, listens for the specific wavelengths glucose throws back, and streams the reading to a phone. The hard part was never the laser. The hard part was making the whole listening apparatus small, cheap, and accurate enough to matter.

From risk ledgers to laser benches

Hong did not arrive from a photonics lab. He arrived from a spreadsheet. His earlier career ran through EY, where he worked as an advisory manager focused on the unglamorous discipline of non-financial risk - the art of cataloguing everything that can go wrong before it does. It is a useful apprenticeship for a man who would later build a company on a technology most investors had written off as impossible to miniaturize.

From consulting he moved into the operator's chair at Genoplan, a consumer genomics venture blending biotechnology with software, where he served as Chief Business Officer, Executive Vice President, and a board director. He learned the grammar of biotech commercialization there - the regulators, the validation, the long road between a clever result and a product someone is allowed to sell. Along the way he picked up a Master of Public Policy from Georgetown University, a credential that reads oddly on a hardware founder's resume until you remember that medical devices are, finally, a fight over policy and proof.

In 2021 he stopped advising other people's bets and made his own. He co-founded Apollon with two scientists - Miyeon Jue, who serves as CTO, and Jun Ki Kim, a professor at Asan Medical Center. The founding premise was almost embarrassingly humane: fewer than one in ten people who could benefit from continuous glucose monitors actually use one. The needles, the cost, the skin irritation, the two-week replacement ritual - each is a small wall, and stacked together they keep most people out.

A handshake that almost never happens

In 2023, Apollon did something that made the Korean tech press sit up: it signed a joint research agreement with MIT's Laser Biomedical Research Center, the same lab lineage behind the original glucose-by-laser work. For a small startup from Seoul, a co-research pact with MIT is not a line item. It is a passport.

Hong did not treat it as a press release. He moved. He relocated his family across the Pacific and planted a subsidiary in Cambridge, close enough to MIT that the collaboration could be measured in walking distance rather than time zones. He has been candid that the move was a leap of faith as much as strategy, and that he leaned hard on the local startup community - MassChallenge among them - to find footing in an unfamiliar market.

Awards are nice. Data is the argument.

In late 2024, Apollon was named a CES 2025 Innovation Award honoree in the Digital Health category. The detail Hong likes to repeat is the company it kept: across the entire field, only three names have won that recognition for this category - Abbott, Dexcom, and Apollon. Two of them are giants. One of them moved to Cambridge two years earlier with a wristband and a thesis.

The award arrived, fittingly, on World Diabetes Day. At CES 2025 Unveiled, Hong put MOGLU on a booth table and watched global manufacturers and overseas investors he could never get on a calendar back home walk over to ask questions. He has since spoken of follow-up conversations with the likes of Medtronic and Samsung Research America - the kind of doors a trade-show ribbon is supposed to open and rarely does.

The recognition has been stacking up on both sides of the Pacific. Before the Las Vegas spotlight, Apollon had already collected a Minister of SMEs and Startups Award, selection into Korea's competitive TIPS program, and an LG Open Innovation Grand Prize - the kind of domestic validation that turns a science project into a fundable company. The roughly $1.9 million seed round that followed is small by the standards of the incumbents Hong is chasing, but it bought the one thing a hardware startup needs most: enough runway to keep shrinking the device and keep gathering proof.

But Hong is an ex-risk manager, and he knows a ribbon is not evidence. The harder currency came in a peer-reviewed paper in the Journal of Diabetes Science and Technology, where the compact, band-pass Raman device posted a mean absolute relative difference of 11.3 - statistically comparable to cleared, needle-based sensors - with zero adverse skin reactions after hours of laser exposure. For a technology long dismissed as too noisy to be practical, that line of data is the whole company in a sentence.

Smaller, cheaper, approved

The next chapters are written in the cautious dialect of clinical milestones. Apollon has miniaturized the device to smaller than a smartwatch and is steering toward larger feasibility studies - a clinical feasibility run slated for Boston Medical Center, and a planned 300-participant study connected to Harvard Medical School's Joslin Diabetes Center - each a stepping stone toward an eventual FDA submission. Hong's stated timeline has always been ambitious: commercialization and approval within roughly five years of the MIT pact.

What makes the story worth watching is not the hardware spec sheet. It is the shape of the bet. Hong took a piece of physics everyone agreed was real and nobody believed was portable, and he is spending his career, his savings, and his family's geography arguing otherwise. He is not promising magic. He is collecting data points until the impossible looks merely difficult, and the difficult looks done.